News Archive

  • Friday, June 5, 2015

     Dr. Xiaojuan Chen awarded the  

  • Monday, February 9, 2015

     We are delighted to announce two of the six inaugural winners of the Department of Medicine’s Samuel Bard Young Investigator Awards are members of the CCTI! The following fellows will present abstracts of their research at Medicine Grand Rounds on the two Research Days for Clinical and Post-doctoral Fellows and Scientists 2014.

    On Wednesday, March 11, 2015:

    Ya-Wen Chen, PhD, Post-doctoral Research Scientist, Division of Pulmonary, Allergy, & Critical Care Medicine: Modeling human branching morphogenesis in vivo

    Larry Luchsinger, PhD, Post-doctoral Research Fellow, Division of Molecular Medicine: Mitochondrial Dynamics Regulate Hematopoietic Stem Cell Function

  • to the CCTI's Dr. Adam Griesemer
    Wednesday, February 4, 2015

    The Irving Institute for Clinical and Translational Research awarded 16 faculty members Irving Institute/Clinical Trials Office Pilot Awards, which provide junior faculty with funds to conduct pilot studies needed to attract future independent funding and our own Dr. Adam Griesemer has been chosen as one of the 2014 awardees!

  • Thursday, January 29, 2015

     Nature Biotech highlighted our paper on twitter:

  • in Science Translational Medicine
    Wednesday, January 28, 2015

     When a patient receives a transplant, a unique population of T lymphocytes emerges to reject the foreign organ. Immunosuppressive medication is therefore necessary to prevent rejection and protect the transplanted kidney. Previously, it had not been possible in humans to identify these specific T cells due to their vast number and diversity; furthermore, this population is unpredictable and distinct for each transplant patient and his or her organ donor. In this paper, we describe a new technique to identify these thousands of T cells before the time of kidney transplantation and then track them over time after transplant circulating in peripheral blood. We used this technique to study six kidney transplant recipients to investigate in a new way what happens to these cells when patients have different clinical outcomes. Some of the patients studied were part of a unique cohort who received combined kidney and bone marrow transplants from the same donor in order to induce tolerance and accept their grafts without life-long immunosuppressive medication. Our T cell tracking analysis provided a deeper understanding of the mechanism of tolerance in these patients. This new technique provides a window into the fate of these donor-specific T cells and has potential as a possible biomarker for predicting and identifying rejection and tolerance in different types of transplant patients.

  • Project: The Immune Privilege of the Hematopoietic Stem Cell Niche
    Monday, January 26, 2015

     Dr. Joji Fujisaki, MD. PhD, was recently awarded a prestigious 2015 Schaefer Research Scholar Award by Columbia University, the selection for which is based upon “outstanding merit for the proposed research and as carried out in the past year; along with the likelihood of outstanding future research. See this link for more information about Dr. Fujisaki's research.

  • Dr. Donna Farber, et al
    Thursday, November 6, 2014

    Mechanisms for human memory T cell differentiation and maintenance have largely been inferred from studies of peripheral blood, though the majority of T cells are found in lymphoid and mucosal sites. We present here a multidimensional, quantitative analysis of human T cell compartmentalization and maintenance over six decades of life in blood, lymphoid, and mucosal tissues obtained from 56 individual organ donors. Our results reveal that the distribution and tissue residence of naive, central, and effector memory, and terminal effector subsets is contingent on both their differentiation state and tissue localization. Moreover, T cell homeostasis driven by cytokine or TCR-mediated signals is different in CD4+ or CD8+ T cell lineages, varies with their differentiation stage and tissue localization, and cannot be inferred from blood. Our data provide an unprecedented spatial and temporal map of human T cell compartmentalization and maintenance, supporting distinct pathways for human T cell fate determination and homeostasis. Click here for the full paper published in the most recent issue of Cell.

  • Friday, October 10, 2014

     Clinical Trials Office Pilot Award from the Irving Institute for Translational Research for a grant entitled: "Combined liver and bone marrow transplantation for the induction of tolerance to liver allografts". The goal of this study is to induce tolerance to liver allografts in a preclinical cynomolgus monkey model through the co-transplantation of donor bone marrow and an enhanced immunological conditioning regimen. 

  • Thursday, May 15, 2014

    New York-Presbyterian/Columbia University Medical Center has opened the Irving Bone Marrow Transplant Unit, a state-of-the-art facility for comprehensive bone marrow transplant (BMT) care. The new unit features 18 inpatient rooms, a high-tech nurses station for individual patient monitoring, and a specialized airflow system to help protect patients with weakened immune systems. The unit is supported by a $20 million gift from Herbert and Florence Irving. Read the entire story here.

  • American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
    Friday, December 13, 2013

    Avoidance of long-term immunosuppression is a desired goal in organ transplantation. Mixed chimerism offers a promising approach to tolerance induction, and we have aimed to develop low-toxicity, nonimmunodepleting approaches to achieve this outcome. In a mouse model achieving fully MHC-mismatched allogeneic bone marrow engraftment with minimal conditioning (3 Gy total body irradiation followed by anti-CD154 and T cell-depleted allogeneic bone marrow cells), CD4 T cells in the recipient are required to promote tolerance of preexisting alloreactive recipient CD8 T cells and thereby permit chimerism induction. We now demonstrate that mice devoid of CD4 T cells and NK cells reject MHC Class I-deficient and Class I/Class II-deficient marrow in a CD8 T cell-dependent manner. This rejection is specific for donor alloantigens, since recipient hematopoiesis is not affected by donor marrow rejection and MHC Class I-deficient bone marrow that is syngeneic to the recipient is not rejected. Recipient CD8 T cells are activated and develop cytotoxicity against MHC Class I-deficient donor cells in association with rejection. These data implicate a novel CD8 T cell-dependent bone marrow rejection pathway, wherein recipient CD8 T cells indirectly activated by donor alloantigens promote direct killing, in a T cell receptor-independent manner, of Class I-deficient donor cells.